Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn.

Abstract

A study of the pharmacokinetic parameters of cefotaxime (CTX) and desacetylcefotaxime (dCTX) in newborns was conducted; the former is commonly used for neonatal infections. The elimination half life of CTX correlated with gestational age (GA) and postnatal age (PNA). Elimination of dCTX was longer permitting a synergistic or additive effect with CTX against Gram-negative bacteria. CTX is indicated in the treatment of neonatal sepsis because of the increasing resistance of Escherichia coli to ampicillin and its good efficacy against group B streptococcus.

• Authors: Y Aujard, F Brion, E Jacqz-Aigrain, M C Kasse, P Chretien, C Criqui, H Mathieu
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) 1989 Jan-Feb Vol. 12 Issue 1 Pg. 87-91 ISSN: 0732-8893 [Print] United States
• PMID: 2653716 (Publication Type: Comparative Study, Journal Article)

Chemical References

• desacetylcefotaxime
• Cefotaxime

Topics

• Cefotaxime (administration & dosage, analogs & derivatives, pharmacokinetics, pharmacology)
• Drug Administration Schedule
• Escherichia coli (drug effects)
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Premature (metabolism)
• Streptococcus agalactiae (drug effects)